BRAND NEW SurgiCube® iVi for anti-VEGF therapies

A new smaller SurgiCube® has been designed because of the increase in anti-VEGF therapies worldwide.

All therapies are performed intraocular and therefore need aseptic operating theatre environment conditions. In Germany and Italy it is required to perform this therapy in a dedicated operating theatre and soon many countries will adopt this very important condition for high quality performance and safe surgical outcomes.

In several University clinics in the Netherlands and in Germany intravitreal injections will be performed in the SurgiCube® iVi. This is a special version of the existing SurgiCube® concept that is acknowledged internationally as an ultra clean treatment facility creating a fully conditioned sterile laminar air flow directly onto the surgical field and the instruments. The SurgiCube® iVi is especially designed for fully sterile use at the polyclinic or outpatient department. Because of its size it can be positioned anywhere and it offers you an instant operating theatre environment to perform your intravitreal injections as safe as possible. Easy logistics, smart workflow, low costs and high efficiency make it possible to establish patient satisfaction at the highest level.

Equal technical specifications of the SurgiCube® iVi offer the same effectiveness and safety as the advanced SurgiCube® so both meet the same validation standards as set internationally by GMP A and ISO 5 classifications. In rest less than 1 CFU/m³ (Colony Forming Units) is measured so it complies with regulations worldwide. A very comprehensive servicing and validation program guarantees a safe installation that offers unlimited operational use 24/7.

The SurgiCube® iVi offers the best environment for both you and your patient.

For further details please contact Jackie Handley on 07711 459763.